Physician profile
Michael A Blain
NPI 1801076146
$6,459.03
in general payments reported to CMS, 2019-2025
40 companies · $905 in 2025
The $905 reported for 2025 was more than what 88% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $810 · 2021: $1,174 · 2022: $1,444 · 2023: $843 · 2024: $785 · 2025: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,533.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $894.08 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $676.77 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Uswm, LLC | $583.11 | 2022-2023 | Zimhi, Lucemyra |
| Vanda Pharmaceuticals INC. | $391.26 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $367.66 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Gilead Sciences, INC. | $351.45 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $296.02 | 2021-2025 | Ingrezza |
| Lilly USA, LLC | $280.53 | 2019-2022 | |
| Axsome Therapeutics, INC. | $269.96 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $258.80 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $220.78 | 2020-2023 | Austedo, Austedo Xr, Uzedy |
| Astrazeneca Pharmaceuticals Lp | $176.99 | 2020-2024 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $167.51 | 2022-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Dexcom, INC. | $155.23 | 2022-2025 | Dexcom G6 Transmitter |
| Braeburn INC. | $148.75 | 2023-2025 | Brixadi |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Blain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.